Yufang Hu Ph.D., R.Ph
Dr. Yufang Hu received his B.S. in Pharmacy from Kaohsiung Medical University in Kaohsiung City, and his M.S. degrees and Ph.D. in Industrial Pharmacy from St. John’s University in New York City. He is a registered pharmacist as well. Before coming back to Taiwan, he had worked for the Bristol-Myers Squibb Pharmaceutical Company (New Jersey), Barr Laboratory (New Jersey), and the ImmuLogic Pharmaceutical Corporation (Boston). From 1999, he joined TTY Biopharm to build up a R&D Center from scratch, to currently include more than 60 scientists. More than 30 prescription drugs were launched through this center, including two liposomal injections. In addition, another two liposomal injections, and more four long-active depot injection products are presently under development. He has solicited and received substantial government grants for more than 3 million USD to support these two special drug delivery systems: liposome and depot injection plate forms. In 2017, he founded EnhanX Biopharm, Inc., a TTY subsidiary company, that focuses on developing special drug delivery systems.
Vice President, Finance & Administration
Mr. Chang joined PharmaEngine in February 2003. He is a certified public accountant (CPA) in Taiwan. He worked at TTY Biopharm as the Director of Stock Affairs Department, and MasterLink Securities and Sampo Securities for many years majored in IPOs in Taiwan. He received his Master degree of Accounting from National Taiwan University, Taipei, Taiwan.
Gregory Liu M.S., R.Ph
Vice President, Translational Science
Mr. Gregory Liu received his B.S. in Pharmacy from Taipei Medical University in Taipei and his M.S. degree in Pharmaceutical Sciences from St. John’s University in New York City. He devoted himself for more than 20 years in pharmaceutical industry. He is a registered pharmacist that had served in Shin-Kong Memorial Medical Center as Specialty Pharmacist for a few years as well. In 1997, he joined AstraZeneca Taiwan as a Clinical Research Manager, in 2001, he joined TTY Biopharm as the Head of Medical Affairs Division. Gregory had participated in many varied activities of new drug development with the expertise in oncology field. From new product evaluation, strategic development planning, clinical strategy to deployment, 100+ candidates were evaluated and managed, 20+ products were successfully launched or kept moved on in clinical development process. In 2015, he joined Beijing CTSMed Co., Lt, one of a local leading CRO (Contract Research Organization) served as the Chief Scientific Officer (CSO). During the business development in Mainland China, he expanded networking with KOLs, scientists, professionals and authorities in China, also enlarged resources from pre-clinical to IND.
Senior Director, Marketing & Sales
Mr. Wu joined PharmaEngine in July 2004. He majored in marketing and sales of oncology products at Novartis (Taiwan) and Kirin (Taiwan), responsible for Glivec®, Aredia®, G-CSF and EPO. Mr. Wu received his Bachelor degree in Pharmacy, Taipei Medical University, Taipei, Taiwan